P2X7 and EGCG have been shown to attenuate murine lupus symptoms by inhibiting the activation of NLRP3 inflammasome, thus can be viewed as a promising therapeutic agent in SLE treatment (134–136). This evidence concerns the gene P2RX7 and systemic lupus erythematosus.